Findings

What do systematic reviews say?

10 questions · 10 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 50%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Amifostine vs no otoprotective intervention · Ototoxicity according to NCICTCv2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Objective and subjective audiometric evaluations were performed, no further information provided
  Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  RR 1.04 [0.76, 1.44]
  1 study · 36 participants
  Low
Direct match · question page
- Amifostine vs no otoprotective intervention · Ototoxicity according to modified Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Audiograms were performed, but no further information provided
  Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  RR 1.07 [0.74, 1.55]
  1 study · 82 participants
  Low
Direct match · question page
- Amifostine vs no otoprotective intervention · Ototoxicity according to NCICTCv2 criteria with intra‐arterial platinum (combined asymptomatic and symptomatic disease) Exact test method not reported
  Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  RR 1.29 [0.94, 1.77]
  1 study · 28 participants
  Low
Direct match · question page
- Amifostine vs no otoprotective intervention · Quality of life
  Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Amifostine vs no otoprotective intervention · Renal toxicity/vomiting/ cardiotoxicity (all grade ≥ 3 according to NCICTCv2 criteria) with intra‐arterial platinum
  Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

Amifostine vs no otoprotective intervention

Ototoxicity according to NCI CTC v2 criteria with intra‐arterial platinum (combined asymptomatic and symptomatic disease) Exact test method not reported · children with cancer treated with platinum‐based therapy

Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intra‐arterial… compared with no otoprotective intervention (low certainty).

1 finding from 1 review

Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
RR 1.29 [0.94, 1.77]
1 study · 28 participants
Low

Amifostine vs no otoprotective intervention

Ototoxicity according to NCI CTC v2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Objective and subjective audiometric evaluations were performed, no further information provided · children with cancer treated with platinum‐based therapy

Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intravenous platinum… compared with no otoprotective intervention (low certainty).

1 finding from 1 review

Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
RR 1.04 [0.76, 1.44]
1 study · 36 participants
Low

Amifostine vs no otoprotective intervention

Ototoxicity according to modified Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Audiograms were performed, but no further information provided · children with cancer treated with platinum‐based therapy

Amifostine showed no clear difference in ototoxicity according to modified Brock criteria with intravenous… compared with no otoprotective intervention (low certainty).

1 finding from 1 review

Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
RR 1.07 [0.74, 1.55]
1 study · 82 participants
Low

Amifostine vs no otoprotective intervention

Tumour response with intra‐arterial platinum (good and partial remission) · children with cancer treated with platinum‐based therapy

Amifostine showed no clear difference in tumour response with intra‐arterial platinum (good and partial… compared with no otoprotective intervention (low certainty).

1 finding from 1 review

Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
RR 1.6 [0.97, 2.63]
1 study · 27 participants
Low

Amifostine vs no otoprotective intervention

Renal toxicity / vomiting/ cardiotoxicity (all grade 3 or higher according to NCI CTCv2 criteria) with intra‐arterial platinum · children with cancer treated with platinum‐based therapy

1 finding from 1 review

Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low